ESRP1 and breast cancer: Finally, similar to theprognostic ability of GRHL2, OVOL, and ΔNP63α25,58,72—factors that can stabilize ahybrid E/M phenotype25,36,53,55—higher levels of ESRP1 have beenassociated with (a) poor OS in breast cancer, (b) poor 5-year progression-freesurvival (PFS) and OS in epithelial ovarian cancer samples,77,78 (c) poor prognosis of distant metastasisin breast cancer samples,79 and(d) enhanced metastasis in colorectal cancer progression.80